Altimmune, Inc. (ALT)
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Their lead product candidate, pemvidutide, is currently in Phase 1b trials for obesity and non-alcoholic steatohepatitis.
Company Overview
Altimmune offers a compelling investment opportunity in the burgeoning obesity and liver disease treatment market, driven by its innovative GLP-1/glucagon dual receptor agonist, pemvidutide, currently in Phase 1b trials, positioning it for significant growth potential in addressing unmet medical needs.
Investment Thesis
Altimmune presents a compelling investment opportunity due to its innovative approach to treating obesity and liver diseases. Pemvidutide, the lead candidate, has shown promising early results in Phase 1b trials, suggesting potential for significant weight loss and improvement in NASH-related markers. The increasing prevalence of obesity and NASH creates a substantial market opportunity. Positive Phase 2 trial results for pemvidutide by late 2026 could serve as a major catalyst, driving significant stock appreciation. Furthermore, the HepTcell program for chronic HBV offers additional upside potential. With a market cap of $0.43 billion, Altimmune may be undervalued relative to its potential, especially if clinical trials continue to yield positive data. The company's focused pipeline and experienced management team further strengthen the investment case.
Key Highlights
- Market Cap of $0.43 billion reflects investor valuation of Altimmune's future potential in the obesity and liver disease treatment market.
- Negative P/E ratio of -5.19 indicates the company is currently unprofitable, typical for clinical-stage biopharmaceutical companies heavily investing in research and development.
- Profit Margin of -419575.0% highlights the significant expenses associated with clinical trials and drug development, expected to improve upon successful commercialization of products.
- Gross Margin of -74700.0% reflects the high cost of research and development relative to current revenue streams, typical for companies in the clinical stage.
- Beta of 0.08 suggests the stock is significantly less volatile than the overall market, potentially appealing to risk-averse investors.
Competitors
Strengths
- Promising lead product candidate, pemvidutide, in Phase 1b trials.
- Dual GLP-1/glucagon receptor agonist mechanism of action.
- HepTcell program targeting chronic HBV infection.
- Experienced management team.
Weaknesses
- Clinical-stage company with no currently approved products.
- High cash burn rate associated with clinical trials.
- Reliance on successful clinical trial outcomes.
- Negative profit and gross margins.
Catalysts
- Upcoming: Phase 2 trial results for pemvidutide in obesity (late 2026).
- Upcoming: Phase 2 trial results for pemvidutide in NASH (late 2026).
- Ongoing: Enrollment and progress in Phase 2 clinical trial for HepTcell in chronic HBV.
- Ongoing: Potential for strategic partnerships or collaborations.
Risks
- Potential: Clinical trial failures or delays for pemvidutide or HepTcell.
- Potential: Regulatory setbacks or rejection of marketing applications.
- Ongoing: Competition from other companies in the obesity, NASH, and HBV markets.
- Ongoing: Dependence on securing additional funding to support clinical development.
- Potential: Patent challenges or intellectual property disputes.
Growth Opportunities
- Pemvidutide for Obesity: The global obesity market is a multi-billion dollar opportunity, driven by increasing prevalence and limited effective treatments. Altimmune's pemvidutide, with its GLP-1/glucagon dual receptor agonist mechanism, has the potential to capture a significant share of this market. Positive Phase 2 trial results by late 2026 could lead to partnerships and eventual commercialization, driving substantial revenue growth.
- Pemvidutide for NASH: Non-alcoholic steatohepatitis (NASH) is a rapidly growing liver disease with no approved therapies. Pemvidutide's mechanism of action may address the underlying causes of NASH, offering a potential first-in-class treatment. Successful clinical trials and regulatory approval could unlock a significant market opportunity, estimated to be in the billions of dollars.
- HepTcell for Hepatitis B: Chronic hepatitis B virus (HBV) infection affects millions worldwide. Altimmune's HepTcell immunotherapeutic aims to provide a functional cure for HBV. Positive Phase 2 trial data could lead to partnerships and further development, addressing a significant unmet medical need and generating revenue.
- Expansion into Other Metabolic Diseases: Altimmune's expertise in metabolic diseases and its GLP-1/glucagon dual receptor agonist platform could be leveraged to develop treatments for other related conditions, such as type 2 diabetes and cardiovascular disease. This could broaden the company's pipeline and create additional revenue streams.
- Strategic Partnerships and Acquisitions: Altimmune could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Alternatively, the company could be an acquisition target for a larger company seeking to expand its presence in the obesity, NASH, or HBV markets.
Opportunities
- Large and growing markets for obesity and NASH treatments.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Expansion into other metabolic disease indications.
- Favorable regulatory environment for drug development.
Threats
- Competition from other companies developing obesity and NASH therapies.
- Clinical trial failures or delays.
- Regulatory hurdles and approval timelines.
- Patent challenges and intellectual property disputes.
Competitive Advantages
- Proprietary GLP-1/glucagon dual receptor agonist platform.
- Patent protection for pemvidutide and HepTcell.
- Clinical data demonstrating efficacy and safety of product candidates.
- Experienced management team with expertise in drug development.
About
Altimmune, Inc., founded in 1997 and headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and liver diseases. Originally named Vaxin Inc., the company rebranded as Altimmune, Inc. in September 2015, signaling a strategic shift towards its current focus. The company's lead product candidate, pemvidutide (formerly ALT-801), is a GLP-1/glucagon dual receptor agonist currently undergoing Phase 1b clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide aims to address the growing global health crisis posed by these conditions. In addition to pemvidutide, Altimmune is also developing HepTcell, an immunotherapeutic product candidate in Phase 2 clinical trials for patients with chronic hepatitis B virus (HBV) infection. Altimmune's pipeline reflects its commitment to addressing significant unmet medical needs in metabolic and liver diseases. With a focused approach and promising clinical data, Altimmune is positioning itself as a key player in the biopharmaceutical landscape, striving to improve patient outcomes and transform the treatment paradigm for obesity, NASH, and HBV.
What They Do
- Develops pemvidutide for the treatment of obesity.
- Develops pemvidutide for the treatment of non-alcoholic steatohepatitis (NASH).
- Develops HepTcell as an immunotherapeutic for chronic hepatitis B virus (HBV) infection.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals from agencies like the FDA for its therapies.
- Focuses on addressing unmet medical needs in metabolic and liver diseases.
- Utilizes a GLP-1/glucagon dual receptor agonist platform for its obesity and NASH programs.
Business Model
- Develops and patents novel therapeutic candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered products.
- Funds research and development through equity financing and potential grants.
FAQ
What does Altimmune, Inc. do?
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 1b trials for obesity and NASH. The company also develops HepTcell, an immunotherapeutic for chronic HBV. Altimmune aims to address unmet medical needs in these areas through innovative therapies, conducting clinical trials and seeking regulatory approvals to bring these treatments to market.
Is ALT stock a good buy?
ALT stock's potential as a buy hinges on the success of its clinical trials, particularly pemvidutide's Phase 2 results expected by late 2026. The company's focus on high-growth markets like obesity and NASH presents a significant opportunity. However, the negative P/E and profit margins reflect its clinical-stage status, indicating higher risk. A positive outlook depends on favorable clinical data, strategic partnerships, and successful navigation of regulatory hurdles. Investors should weigh the potential reward against the inherent risks of biopharmaceutical development.
What are the main risks for ALT?
The primary risks for Altimmune include clinical trial failures or delays, which could significantly impact the company's valuation. Regulatory hurdles and potential rejection of marketing applications also pose substantial risks. Competition from other companies developing similar therapies is another concern. Furthermore, Altimmune's reliance on securing additional funding to support its clinical programs exposes it to financial risks, especially if clinical data is unfavorable or market conditions deteriorate.
Industry Context
Altimmune operates in the biotechnology industry, specifically targeting the obesity and liver disease markets. These markets are experiencing significant growth due to the rising prevalence of obesity, NASH, and HBV worldwide. The competitive landscape includes companies like Amarin (AMRN) and others developing treatments for related conditions. The global obesity market is projected to reach billions of dollars in the coming years, presenting a substantial opportunity for Altimmune. Success in clinical trials and regulatory approvals are critical for companies in this space.
Key Customers
- Patients suffering from obesity.
- Patients diagnosed with non-alcoholic steatohepatitis (NASH).
- Patients chronically infected with the hepatitis B virus (HBV).
- Pharmaceutical companies seeking to license or acquire novel therapeutics.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5,000 | -$19M | $-0.21 |
| Q2 2025 | $5,000 | -$22M | $-0.27 |
| Q1 2025 | $5,000 | -$20M | $-0.26 |
| Q4 2024 | $5,000 | -$23M | $-0.33 |
Source: Company filings
Chart & Info
Price Chart
Altimmune, Inc. (ALT) stock price: $4.09 (+0.58, +16.52%)
Why Bull
- •Recent insider buying suggests confidence in Altimmune's future prospects, indicating a belief in the company's potential growth.
- •Community sentiment has shifted positively, with discussions highlighting the promising results from recent clinical trials.
- •Altimmune's focus on innovative therapies is resonating well with investors, creating a buzz around its pipeline.
- •The overall market perception is improving as Altimmune gains recognition in the biopharmaceutical sector, attracting more attention from retail investors.
Why Bear
- •Concerns about the competitive landscape in the biotech industry could dampen enthusiasm, as rivals may have more advanced products.
- •Recent social sentiment has shown some skepticism regarding the timeline for product approvals, leading to uncertainty among investors.
- •Insider selling activity in the past raised flags about potential challenges ahead, causing some investors to reassess their positions.
- •Market volatility and macroeconomic factors could overshadow Altimmune's advancements, making it harder for the stock to gain traction.
Latest News
-
ALT5 Sigma Corporation Appoints Dr. Adel Elmessiry to Board of Directors
accessnewswire.com · Feb 12, 2026
-
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Yahoo! Finance: ALT News · Feb 3, 2026
-
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Yahoo! Finance: ALT News · Feb 2, 2026
-
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Insider Monkey · Feb 2, 2026
Technical Analysis
Rationale
AI-generated technical analysis for ALT including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Altimmune, Inc. (ALT) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for ALT.
Make a Prediction
Set your price target for Altimmune, Inc. (ALT), choose a timeframe, and track your prediction accuracy.
Current price: $4.09
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALT.
Price Targets
Median: $20.00 (+389.0% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
- Revenue Growth 2/100
- Gross Margin 3/100
- Operating Leverage 4/100
- Cash Runway 5/100
- R&D Intensity 10/100
- Insider Activity 6/100
- Short Interest 4/100
- Price Momentum 0/100
- News Sentiment 5/100
What does this score mean?
The MoonshotScore rates ALT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
ALT5 Sigma Corporation Appoints Dr. Adel Elmessiry to Board of Directors
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Frequently Asked Questions
What does Altimmune, Inc. do?
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 1b trials for obesity and NASH. The company also develops HepTcell, an immunotherapeutic for chronic HBV. Altimmune aims to address unmet medical needs in these areas through innovative therapies, conducting clinical trials and seeking regulatory approvals to bring these treatments to market.
Is ALT stock a good buy?
ALT stock's potential as a buy hinges on the success of its clinical trials, particularly pemvidutide's Phase 2 results expected by late 2026. The company's focus on high-growth markets like obesity and NASH presents a significant opportunity. However, the negative P/E and profit margins reflect its clinical-stage status, indicating higher risk. A positive outlook depends on favorable clinical data, strategic partnerships, and successful navigation of regulatory hurdles. Investors should weigh the potential reward against the inherent risks of biopharmaceutical development.
What are the main risks for ALT?
The primary risks for Altimmune include clinical trial failures or delays, which could significantly impact the company's valuation. Regulatory hurdles and potential rejection of marketing applications also pose substantial risks. Competition from other companies developing similar therapies is another concern. Furthermore, Altimmune's reliance on securing additional funding to support its clinical programs exposes it to financial risks, especially if clinical data is unfavorable or market conditions deteriorate.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.